The technology underlying subunit vaccines for class I and III enveloped virus. It is made to elicit a protective immune response by producing stabilized fusion proteins which can remain primarily in their pre-fusion form.
The technology underlying subunit vaccines for class I and III enveloped virus. It is made to elicit a protective immune response by producing stabilized fusion proteins which can remain primarily in their pre-fusion form. Researchers have used molecular clamp technology to create chimeric polypeptides mimicking the pre-fusion conformations of influenza, RSV, HIVHIV, measles, and Ebola.
The technology underlying subunit vaccines for class I and III enveloped virus. It is made to elicit a protective immune response by producing stabilized fusion proteins which can remain primarily in their pre-fusion form.
The technology underlying subunit vaccines for class I and III enveloped virus. It is made to elicit a protective immune response by producing stabilized fusion proteins which can remain primarily in their pre-fusion form. Researchers have used molecular clamp technology to create chimeric polypeptides mimicking the pre-fusion conformations of influenza, RSV, HIV, measles, and Ebola.
The technology underlying subunit vaccines for class I and III enveloped virus. It is made to elicit a protective immune response by producing stabilized fusion proteins which can remain primarily in their pre-fusion form.